Illumina Inc (ILMN) Return on Assets ROA from the second quarter of 2026 to second quarter of 2025 and for the year 2026, Average High and Low, Fundamental Ratios from Jun 28 2026 to Jun 29 2025 - CSIMarket
CSIMarket
 


Illumina Inc   (NASDAQ: ILMN)


Illumina Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics


What is Illumina Inc 's ROA in the second quarter of 2026?
Illumina Inc achieved a return on average assets (ROA) of 12.64 % in its second quarter of 2026, this is above ILMN's average return on assets of 4.14%.
Illumina Inc s assets during the 12 months ending in the second quarter of 2026 are valued at $6 billion

ROA fell compared to the first quarter of 2026, despite the net income growth of 54.48% from the first quarter of 2026.

However, within the Healthcare sector 77 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 28 2026 quarter, so far to 419, from total ROA ranking in the first quarter of 2026 at 470.

What is ROA?



Return On Assets (Jun 28 2026)
II. Quarter
(Mar 29 2026)
I. Quarter
(Dec 28 2025)
IV. Quarter
(Sep 28 2025)
III. Quarter
(Jun 29 2025)
II. Quarter
Y / Y Total Assets Change 9.25 % 6.1 % 26.48 % 24.94 % 22.01 %
Y / Y Net Income Change -11.91 % 2.29 % 79.57 % -78.72 % -
Net Income (TTM) in million 825 853 850 702 1,257
Return On Assets (TTM) 12.64 % 13.36 % 13.51 % 11.82 % 22.32 %
ILMN's Total Ranking # 419 # 470 # 539 # 236 # 3517
Total Assets (TTM) in million 6,650 6,559 6,725 6,177 6,087
Seq. Total Assets Change 1.39 % -2.47 % 8.87 % 1.48 % -1.54 %
Seq. Net Income Change 54.48 % -59.88 % 122.67 % -36.17 % 79.39 %



Return On Assets Company Ranking
Within: No.
Industry # 3
Sector # 78
Overall # 455

Return On Assets Statistics
High Average Low
20.45 %
4.14 %
-35.56 %
(Jun 29 2025)   (Jul 02 2023)





Financial Statements
Illumina Inc 's Assets $ 6,650 million ILMN's Balance sheet
Illumina Inc 's Income $ 207 million Quarterly ILMN's Income Statement
ILMN's Income by Division See ILMN's Income by Division



Annual Return On Assets (Dec 28 2025)
FY 2025
(Dec 29 2024)
FY 2024
(Dec 31 2023)
FY 2023
(Jan 01 2023)
FY 2022
(Jan 02 2022)
FY 2021
Y / Y Total Assets Change 24.96 % -44.42 % -17.52 % -20.25 % 106.81 %
Total Assets in million 6,644 5,317 9,567 11,599 14,545
Y / Y Net Income Change - - - - 16.16 %
Net Income in million 850 -1,223 -1,161 -4,404 762
Annual Return On Assets 12.79 % -23 % -12.14 % -37.97 % 5.24 %




Comment on ILMN's ROA in the fiscal year ending 2025
In the fiscal year 2025 ROA improved to 12.79 % compared to prior year, due to annual net income growth of % to $850.00 million, while value of Illumina Inc 's overall assets grew just by 24.96 % to $6,644.00 million, compared to $6,644.00 a year before.


More Return On Assets Ratios
ILMN's' Return on Assets at Yahoo Finance
Laboratory Analytical Instruments Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
ILMN's Roa Ratio versus Laboratory Analytical Instruments Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for ILMN's Competitors
Subscribers only: Roa for Illumina Inc 's Suppliers
Subscribers only: Return On Assets for ILMN's Customers

You may also want to know
ILMN's Roi ILMN's Inventory Turnover Ratio ILMN's Growth Rates ILMN's Dividend Comparisons
ILMN's Profitability Ratios ILMN's Asset Turnover Ratio ILMN's Dividend Growth
ILMN's Roe ILMN's Valuation Ratios ILMN's Financial Strength Ratios ILMN's Dividend Payout Ratio



Companies with similar Return On Assets at Jun 28 2026, within Healthcare Sector ROA
Ironwood Pharmaceuticals inc   34.34 %
Idexx Laboratories Inc  33.61 %
Tg Therapeutics Inc   33.59 %
Meiragtx Holdings Plc  29.37 %
Indivior Pharmaceuticals Inc   28.21 %
Qhslab Inc   27.12 %
Adma Biologics Inc   26.58 %
Mettler toledo International Inc   24.86 %
Medpace Holdings Inc   24.84 %
Caredx Inc   24.81 %
Acadia Pharmaceuticals Inc   24.38 %
Eli Lilly And Company  21.97 %
Innoviva Inc   21.64 %
Vaxart Inc   20.85 %
Zevra Therapeutics Inc   20.39 %
Iradimed Corporation  20.36 %
Protalix Biotherapeutics inc   20.09 %
Pro dex Inc   19.87 %
Electromed Inc   19.39 %
United Therapeutics Corporation  17.98 %
Resmed Inc   17.80 %
Krystal Biotech Inc   17.65 %
Chemed Corporation  17.52 %
Zoetis Inc   17.19 %
Vertex Pharmaceuticals Inc  16.88 %
Halozyme Therapeutics Inc   16.55 %
Alnylam Pharmaceuticals Inc   15.76 %
Intuitive Surgical Inc   15.63 %
Healthcare Services Group Inc   15.21 %
Inspire Medical Systems inc   15.21 %


Date modified: 2026-08-30T22:16:52+00:00


Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.